IRVINE, CA and AMSTERDAM, THE NETHERLANDS, August 9, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that Stefan Glück, MD, PhD, will lead the company’s Medical Advisory Board. As Chairman, Dr. Glück is assembling a panel of leading medical oncologists, surgeons, scientists and pathologists to play a key role in advising Agendia on the clinical application of its extensive product pipeline, including its Symphony™ suite of FFPE based tests for breast cancer and its ColoPrint test for colon cancer.
“Agendia is at the forefront of the personalized medicine revolution, and as a medical oncologist, I am very excited and honored to collaborate with the company at such a critical time,” said Dr. Glück. “With a robust pipeline of new cancer profiles in development, I look forward to applying my knowledge and expertise to facilitate diagnosis, prognosis and cancer diagnostic development.”
Dr. Glück is a Sylvester Professor at the Miller School of Medicine at the University of Miami in Florida. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute. Before his move to Miami, Dr. Glück was Director, Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center, and a Professor in the departments of oncology, medicine, pharmacology and therapeutics at the University of Calgary in Alberta, Canada, and Deputy Head, Department of Oncology at the University of Calgary.
“Dr. Glück brings over 20 years of clinical experience in the medical profession to Agendia’s Medical Advisory Board,” said David Macdonald, CEO of Agendia. “Agendia is committed to advancing the future of personalized medicine through the development of new diagnostic tests. Dr. Glück’s extensive knowledge and vast experience will provide our Medical Advisory Board with strong leadership as we continue to bring Agendia’s rich product pipeline to market.”
Dr. Glück was presented the America’s Top Oncologists award from Consumers’ Research Council of America. He was also recognized as one of the Best Doctors in America from 2006 through 2012. He has authored or co-authored more than 200 articles. In addition, Dr Glück has written or co-written a number of book chapters and numerous journal abstracts, and he has presented more than 350 papers at national and international meetings.
Dr Glück completed his medical studies at the Free University of West Berlin, Germany. The internship in Berlin was followed by residency in internal medicine and fellowship in hematology at the Heinrich Heine Universität in Düsseldorf, Germany, and a medical oncology and bone marrow transplant fellowship at the Princess Margaret Hospital, University of Toronto in Canada.
About Agendia:
Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient’s individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.
In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.
For more information, please visit
For further information, please contact:
Melissa Hurley
Tel: +1 646 442 2773